30 closest matches · ranked by relevance
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
Liver Diseases · Portal Hypertension
Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Portal Hypertension · Liver Cirrhosis
Primary: Safety (Incidence and Severity of Adverse Events) — 23; 2 Number of adverse events
Clinically Significant Portal Hypertension
Primary: Patients With Change in HVPG From Baseline — 1; 1 participants
Patients With Compensated Liver Cirrhosis
Primary: CSPH (Clinically Significant Portal Hypertension) — 81.82 percentage of agreement
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Hepatitis C · Cirrhosis · Portal Hypertension
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 72.0; 0; 71.4 percentage of participants
Compensated Cirrhosis and Portal Hypertension
Primary: Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Serelaxin Treatment Group Only)) — 0.438 L/min
NASH - Nonalcoholic Steatohepatitis · Cirrhosis · Portal Hypertension
Primary: Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT) — 190…
Liver Resection · Cancer
Primary: Changes in Liver Remnant Volume — 18.4; 80.7 percentage change
Liver Cirrhosis · Hypertension, Portal
Primary: Variceal Bleeding Events — 3; 3 Participants
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Compensated Cirrhosis · Nonalcoholic Steatohepatitis
Primary: Change From Baseline in Enhanced Liver Fibrosis Score at Week 48 — -0.071; 0.125; -0.213; 0.263 score on a scale
Carcinoma, Hepatocellular
Primary: Number of Participants With the Development of Hepatocellular Carcinoma (HCC) — 15; 11 Participants
Cirrhosis · Aerobic Exercises · Lifestyle Modification
Primary: Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN — 75.87; 55.13; -4.77; -14.91 milliseconds — p=0.64
Hypertension, Portal
Primary: Change in Portal Pressure at Year 1 (Change in HVPG From Baseline and 1 Year) — -0.39; -0.24; 0.19 mm HG — p=1.000
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12) — 100.0…
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Cirrhosis, Liver
Primary: Enrollment Rate — 20; 20 Participants
Liver Cirrhosis · Portal Vein Thrombosis
Primary: Recanalization Rate — 20; 11 Participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…
Hepatitis C · Liver Cirrhosis
Primary: AUC 0-∞ — 7240; 24700 h*ng/mL